{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:37:46Z","timestamp":1782207466011,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.autrev.2020.102589","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:50:24Z","timestamp":1591962624000},"page":"102589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Cesare","family":"Mazzaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Dal Maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endri","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Visentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Tonizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Pozzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102589_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2020.102589_bb0010","first-page":"SII20","article-title":"HCV and cryoglobulinemic vasculitis","volume":"69","author":"Ferri","year":"2002","journal-title":"Clin J Med"},{"key":"10.1016\/j.autrev.2020.102589_bb0015","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102589_bb0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.7326\/0003-4819-129-4-199808150-00005","article-title":"Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection","volume":"129","author":"Andreone","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2020.102589_bb0025","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.autrev.2020.102589_bb0030","series-title":"Monographs on the evaluation of carcinogenic risks to humans volume 100 part B: A review of human carcinogens: Biological agents","author":"IARC","year":"2012"},{"key":"10.1016\/j.autrev.2020.102589_bb0035","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations associated with hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2020.102589_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias","volume":"165","author":"Monti","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2020.102589_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4254\/wjh.v8.i2.107","article-title":"Hepatitis C virus and non-Hodgkin\u2019s lymphomas: metanalysis od epidemiology data and therapy options","volume":"8","author":"Pozzato","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0050","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lynphomas associated with HCV infection: a study of the fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2020.102589_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lympocites after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102589_bb0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","article-title":"Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas","volume":"145","author":"Mazzaro","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102589_bb0065","first-page":"933","article-title":"Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study","volume":"29","author":"Mazzaro","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients","volume":"10","author":"Pietrogrande","year":"2011","journal-title":"Autoimmunity Rev"},{"key":"10.1016\/j.autrev.2020.102589_bb0075","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"issue":"9956","key":"10.1016\/j.autrev.2020.102589_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"9973","key":"10.1016\/j.autrev.2020.102589_bb0085","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102589_bb0090","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirirn for hepatitis C virus-associated cryoglobulinaemia vasculitits: VASCULVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102589_bb0095","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2020.102589_bb0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1389450117666160208145432","article-title":"Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study","volume":"18","author":"Gragnani","year":"2017","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.autrev.2020.102589_bb0105","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2020.102589_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102589_bb0115","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia","volume":"112","author":"Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102589_bb0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated Cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-017-1280-6","article-title":"Direct-acting agents in the therapy of hepatitis C virus related mixed cryoglobulinemia: a single Centre experience","volume":"19","author":"Lauletta","year":"2017","journal-title":"Arthr Res Ther"},{"issue":"Suppl. 111","key":"10.1016\/j.autrev.2020.102589_bb0130","first-page":"161","article-title":"Recurrence of mixed cryoglobulinaemia vasculitis following influenza vaccination despite clearance of hepatitis C virus infection","volume":"36","author":"Sollima","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 111","key":"10.1016\/j.autrev.2020.102589_bb0135","first-page":"107","article-title":"Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia: a multicentre open-label study","volume":"36","author":"Mazzaro","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0140","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated Cryoglobulinemia Vasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0145","author":"American Association for the study of the liver Disease (AASLD)"},{"key":"10.1016\/j.autrev.2020.102589_bb0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for the study of the liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.autrev.2017.11.035","article-title":"Cryoglobulins: an update on detection, mechanisms and clinical contribution","volume":"17","author":"Kolopp-Sarda","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102589_bb0160","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.autrev.2019.06.008","article-title":"Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome","volume":"18","author":"Galli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102589_bb0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFN\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryglobulinemia vasculitis","volume":"62","author":"Saadoun","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0170","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","volume":"55","author":"Sollima","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102589_bb0175","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/ajg.2017.294","article-title":"Direct-acting antivirals and mixed Cryoglobulinemia Vasculitis: long-term outcome of patients achieving HCV eradication","volume":"112","author":"Sollima","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102589_bb0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-term outcomes of patients with HCV-associated cryoglobulinemic Vasculitis after virologic cure","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102589_bb0185","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/liv.14053","article-title":"Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis","volume":"39","author":"Visentini","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2020.102589_bb0190","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.23305","article-title":"Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response","volume":"58","author":"Landau","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102589_bb0195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.ajkd.2017.01.041","article-title":"Recurrent mixed Cryoglobulinemia despite sustained Virologic response to treatment: a case report","volume":"70","author":"Chowdhury","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2020.102589_bb0200","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/key157","article-title":"Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer","volume":"57","author":"Visentini","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102589_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2017-03-771238","article-title":"Reversion of anergy signatures in clonal CD21 low B cells of mixed cryoglobulinemia after clearance of HCV viremia","volume":"130","author":"Del Padre","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102589_bb0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2017-05-786368","article-title":"Persistence of exhaustion in cured hep C","volume":"130","author":"Kaplan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102589_bb0215","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/MEG.0000000000001239","article-title":"Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? Virological, immunological, and clinical data from a real-life experience","volume":"30","author":"Passerini","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11926-019-0859-0","article-title":"Understanding the Cryoglobulinemias","volume":"21","author":"Fuentes","year":"2019","journal-title":"Understanding the cryoglobulinemia Curr Rheum TOL Rep"},{"key":"10.1016\/j.autrev.2020.102589_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17474124.2018.1411802","article-title":"Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of hepatitis C","volume":"12","author":"Hubbard","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0230","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2017.1282459","article-title":"A pangenotypic, single tablet regimen of sofosbuvir\/velpatasvir or the treatment of chronic hepatitis C infection","volume":"18","author":"Weisberg","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2020.102589_bb0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1756283X16671293","article-title":"Grazoprevir\/elbasvir combination therapy for HCV infection","volume":"10","author":"Vallet-Pichard","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102589_bb0240","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/hep.28981","article-title":"Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy","volume":"65","author":"Artemova","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2020.102589_bb0245","unstructured":"Scarpato S, Galassi G, Monti G, Mazzaro C, Mascia M, Scaini P, et al. Peripheral neuropathy in Mixed Cryoglobulinaemia: clinical assessment and therapeutic approach. Clin Exper Rheumatol 2020 ((in Press) article code: CER13359 revision (20200414220423\u201315529))."},{"key":"10.1016\/j.autrev.2020.102589_bb0250","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2796.2000.00627.x","article-title":"Hepatitis C virus risk: a hepatitis C virus related syndrome","volume":"247","author":"Mazzaro","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2020.102589_bb0255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/pathogens8040176","article-title":"Direct-acting antiviral agents for HCV-associated glomerular disease and the current evidence","volume":"8","author":"Fabrizio","year":"2019","journal-title":"Pathogens"},{"issue":"Suppl","key":"10.1016\/j.autrev.2020.102589_bb0260","first-page":"91","article-title":"Clinical Practice Guideline for the prvention, diagnosis, evaluation, and treatment of hepatitis C chronic kidney disease","volume":"8","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2020.102589_bb0265","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2604::AID-CNCR26>3.0.CO;2-V","article-title":"Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy","volume":"77","author":"Mazzaro","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2020.102589_bb0270","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1365-2141.2001.02571.x","article-title":"Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment","volume":"112","author":"Patriarca","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102589_bb0275","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin\u2019s lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5 Suppl 7","key":"10.1016\/j.autrev.2020.102589_bb0280","first-page":"18","article-title":"A review of the clinical studies of alpha-interferon in the management of multiple myeloma","volume":"18","author":"Cooper","year":"1991","journal-title":"Semin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2020.102589_bb0285","first-page":"24","article-title":"The treatment of hairy cell leukemia: an update","volume":"6","author":"Golomb","year":"1992","journal-title":"Leukemia"},{"issue":"3 Suppl 2","key":"10.1016\/j.autrev.2020.102589_bb0290","first-page":"35","article-title":"Alpha interferon treatment of low-grade B-cell non-Hodgkin\u2019s lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia","volume":"13","author":"Foon","year":"1986","journal-title":"Semin Oncol"},{"key":"10.1016\/j.autrev.2020.102589_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428199609067578","article-title":"Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia","volume":"21","author":"Jewell","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.autrev.2020.102589_bb0300","first-page":"413","article-title":"Low-dose \u201cnatural\u201d alpha-interferon in B-cell derived chronic lymphocytic leukemia","volume":"77","author":"Pozzato","year":"1992","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2020.102589_bb0305","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102589_bb0310","doi-asserted-by":"crossref","first-page":"18544","DOI":"10.1073\/pnas.0509402102","article-title":"Activation of na\u00efve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders","volume":"102","author":"Rosa","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102589_bb0315","article-title":"Hepatitis C virus infection and lymphoma","volume":"2","author":"Bachy","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.autrev.2020.102589_bb0320","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102589_bb0325","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.3748\/wjg.v22.i27.6214","article-title":"Hepatitis C virus-associated B cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Mih\u0103il\u0103","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102589_bb0330","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102589_bb0335","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archderm.139.3.391","article-title":"Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment","volume":"139","author":"Auzerie","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2020.102589_bb0340","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:57Z","timestamp":1761599937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220301531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1568997220301531"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102589","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102589"}}